IFNA1 and COVID-19: For instance, Bastard et al. (2020) [76] found that anti-IFN-α and anti-IFN-ω autoantibodies were present in at least 10% of patients with life-threatening COVID-19 and demonstrated that these antibodies had an in vitro neutralizing activity sufficient to impair antiviral activity against SARS-CoV-2.